Cancer
Malignant Lung Neoplasm
CI-CAN-00001140Explore in graph →
Top-level2,648 active trials51 approved drugs619 evidence items
- NCIt
- C7377
- ICD-10
- C33-C34
- DOID
- 1324
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001140Explore in graph →
Clinical trials
11,122 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,489)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01242072 | Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies | completed | Phase 1 | 22 | Alaunos TherapeuticsINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07847138 | The Effect of Music on Anxiety and Caregiver Burden in Family Caregivers of Patients With Lung Cancer | completed | N/A | 50 | Izmir Bakircay UniversityOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05753722 | A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies | completed | Phase 1 | 79 | Incendia TherapeuticsINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03568656 | Study to Evaluate CCS1477 in Advanced Tumours | completed | Phase 1 / Phase 2 | 219 | CellCentric Ltd.INDUSTRY | 6 | Sep 25, 2026 | clinicaltrials |
| NCT05269485 | Hypofraction Radiotherapy for Locally Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 36 | Anhui Provincial HospitalOTHER_GOV | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06799286 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer | completed | Phase 1 | 10 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07838532 | Real-World Study of Aumolertinib in Patients With Advanced EGFR T790M-Positive NSCLC(AUMO-RWE) | completed | — | 637 | Xin LiOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05312840 | Efficacy and Safety of Conventional and Low-dose Platinum Gemcitabine Combined With Sintilimab With Delayed Administration in First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer | completed | Phase 2 | 20 | People's Hospital of QuzhouOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT00340405 | Development of a Biologic Specimen Bank for the Study of Early Markers of Lung Cancer Among Tin Miners in Yunnan, China | completed | — | 9,759 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT01350817 | Erlotinib and Docetaxel in Second Line of Treatment in Patients With Non Small Cell Lung Cancer(TARSEQ) | completed | Phase 2 | 156 | University Hospital, LimogesOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05153239 | Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON) | completed | Phase 3 | 705 | PharmaMarINDUSTRY | 24 | Sep 21, 2026 | clinicaltrials |
| NCT07550764 | Effect of Infrared-Assisted Intravenous Catheterization on Patient Comfort and Nurse-Patient Trust in Lung Cancer Patients | completed | N/A | 160 | Ataturk UniversityOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04665856 | Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer(SKYSCRAPER-02C) | completed | Phase 3 | 123 | Hoffmann-La RocheINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05017025 | Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 32 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05801133 | Pifenidone Prophylactic Therapy for Radiation Lung Injury in Patients Who Have Previously Received Immune Checkpoint Inhibitors | completed | Phase 2 | 41 | Hubei Cancer HospitalOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06863623 | The Effect of Immersive Virtual Reality and Relaxing Videos on Lung Cancer Patients | completed | N/A | 315 | Hacettepe UniversityOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07827885 | 20-Fr Versus 24-Fr Chest Drains After Uniportal VATS Lobectomy for NSCLC(DRAIN2024) | completed | N/A | 80 | Fondazione Policlinico Universitario Campus Bio-MedicoOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT02704832 | Role of Geriatric Intervention in Treatment of Older Patients With Cancer (PREPARE)(PREPARE) | completed | N/A | 792 | Institut BergoniéOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT04544748 | A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies | completed | Phase 1 | 48 | AO GENERIUMINDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06546839 | SPSIPB vs SAPB for Thoracoscopic Surgery | completed | N/A | 46 | Medipol UniversityOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07824778 | Construction and Application Research of a Multidisciplinary Combined Exercise Management Program for Elderly Lung Cancer Patients After Surgery Based on Social Cognitive Theory | completed | N/A | 68 | Sir Run Run Shaw HospitalOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07785791 | ERAS Compliance and Nutritional Outcomes After Lung Cancer Surgery(ERAS-NUTRI) | completed | — | 120 | Bursa City HospitalOTHER_GOV | 1 | Sep 16, 2026 | clinicaltrials |
| NCT02273375 | Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC | completed | Phase 3 | 1,415 | Canadian Cancer Trials GroupNETWORK | 19 | Sep 14, 2026 | clinicaltrials |
| NCT05858736 | Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors(PRESERVE-009) | completed | Phase 1 | 18 | OncoC4, Inc.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05882734 | Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) | completed | Phase 1 / Phase 2 | 61 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 8 | Sep 14, 2026 | clinicaltrials |
| NCT06501378 | Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Active Brain Metastasis | completed | Phase 2 | 40 | Fudan UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT00632853 | Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide | completed | Phase 3 | 731 | Alliance for Clinical Trials in OncologyOTHER | 4 | Sep 10, 2026 | clinicaltrials |
| NCT07257549 | Real-Time Non-Invasive Localization for Multiple Lung Nodules | completed | N/A | 120 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT02675829 | Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers | completed | Phase 2 | 131 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04838548 | A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 87 | Lepu Biopharma Co., Ltd.INDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT03906071 | Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer(SAPPHIRE) | completed | Phase 3 | 577 | Mirati Therapeutics Inc.INDUSTRY | 12 | Sep 8, 2026 | clinicaltrials |
| NCT06574295 | HTA of NIVATS Based on RWE | completed | — | 876 | Fudan UniversityOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT04909164 | The Prospective Non-randomized Case-control Study From Real-world Lung Cancer Patients(OPTIMUS) | completed | — | 1,519 | Myung-Ju AhnOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06790355 | ProSight: A Multi-centre Interventional Study Evaluating MCED in Asymptomatic Population | completed | N/A | 2,527 | Shanghai Weihe Medical Laboratory Co., Ltd.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06827132 | Observational Study Evaluate Pathology Practice Use Artificial Intelligence in Patient Suspected Lung and Breast Cancer(CASCADE) | completed | — | 603 | AstraZenecaINDUSTRY | 2 | Sep 3, 2026 | clinicaltrials |
| NCT05864144 | A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 98 | Sensei Biotherapeutics, Inc.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT03948724 | Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology(EDHITO) | completed | N/A | 412 | Institut Cancerologie de l'OuestOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT03375242 | Safety and Efficacy of Xalkori ROS1 | completed | — | 97 | PfizerINDUSTRY | 1 | Aug 28, 2026 | clinicaltrials |
| NCT05298423 | Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)(KEYVIBE-006) | completed | Phase 3 | 610 | Merck Sharp & Dohme LLCINDUSTRY | 25 | Aug 28, 2026 | clinicaltrials |
| NCT05299125 | Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations(AMIGO-1) | completed | Phase 2 | 54 | Latin American Cooperative Oncology GroupOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT04222335 | Understanding and Overcoming the Early Adaptive Resistance to EGFR Tyrosine-kinase Inhibitors in Lung Cancer Patients(LUNG-RESIST) | completed | N/A | 47 | University Hospital, ToulouseOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06478043 | A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for SCLC | completed | Phase 2 | 60 | Zhejiang Cancer HospitalOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT01562028 | BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)(BELIEF) | completed | Phase 2 | 109 | ETOP IBCSG Partners FoundationNETWORK | 8 | Aug 26, 2026 | clinicaltrials |
| NCT01652469 | Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®.(EMPHASIS) | completed | Phase 3 | 81 | ETOP IBCSG Partners FoundationNETWORK | 12 | Aug 26, 2026 | clinicaltrials |
| NCT04209595 | PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers | completed | Phase 1 / Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05176860 | Evaluation of Novel Cone-Beam CT for Guidance and Adaptation of Precision Radiotherapy | completed | N/A | 31 | Varian, a Siemens Healthineers CompanyINDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06863233 | A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer | completed | Phase 1 | 4 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT04670445 | Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer(UPLIFT) | completed | N/A | 199 | Massachusetts General HospitalOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT02046733 | Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease(STIMULI) | completed | Phase 2 | 222 | ETOP IBCSG Partners FoundationNETWORK | 8 | Aug 24, 2026 | clinicaltrials |
Data updated 11 hours agoSource updated Sep 29, 2026source: clinicaltrials